ID   UBR4_HUMAN              Reviewed;        5183 AA.
AC   Q5T4S7; A8MPT2; A8MQ33; A8MQB1; O60646; O75050; Q4QRK5; Q5T4S8;
AC   Q5T4S9; Q5TBN8; Q5TBP2; Q6DKH8; Q6P4A4; Q7L8P7; Q8IXJ4; Q8TDN5;
AC   Q8WV67; Q9HA46; Q9P2N9; Q9UG82;
DT   15-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 1.
DT   10-MAY-2017, entry version 132.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR4;
DE            EC=2.3.2.27;
DE   AltName: Full=600 kDa retinoblastoma protein-associated factor;
DE   AltName: Full=N-recognin-4;
DE   AltName: Full=RING-type E3 ubiquitin transferase UBR4;
DE   AltName: Full=Retinoblastoma-associated factor of 600 kDa;
DE            Short=RBAF600;
DE            Short=p600;
DE   AltName: Full=Zinc finger UBR1-type protein 1;
GN   Name=UBR4; Synonyms=KIAA0462, KIAA1307, RBAF600, ZUBR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH RB1 AND CALM,
RP   IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RX   PubMed=16214886; DOI=10.1073/pnas.0507458102;
RA   Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K.,
RA   Sawada J., Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.;
RT   "p600, a unique protein required for membrane morphogenesis and cell
RT   survival.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   PROTEIN SEQUENCE OF 166-185; 435-443; 850-857; 921-931; 1065-1079;
RP   1131-1141; 1175-1192; 1195-1208; 1286-1293; 1337-1349; 1434-1440;
RP   1464-1470; 1478-1489; 1731-1757; 1838-1850; 1875-1886; 1909-1918;
RP   1921-1931; 2048-2058; 2131-2138; 2211-2218; 2354-2381; 2527-2536;
RP   2564-2572; 2713-2721; 2981-2989; 3046-3065; 3229-3238; 3243-3252;
RP   3589-3606; 3618-3628; 3735-3745; 3809-3816; 3827-3836; 3845-3857;
RP   3889-3915; 4131-4142; 4204-4215; 4320-4334; 4414-4426; 4608-4637;
RP   4686-4696; 4717-4724; 4803-4814; 4852-4860; 5013-5022 AND 5062-5069,
RP   PHOSPHORYLATION AT SER-2719, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 779-5183 (ISOFORM 5).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2908-5183 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455484; DOI=10.1093/dnares/4.5.345;
RA   Seki N., Ohira M., Nagase T., Ishikawa K., Miyajima N., Nakajima D.,
RA   Nomura N., Ohara O.;
RT   "Characterization of cDNA clones in size-fractionated cDNA libraries
RT   from human brain.";
RL   DNA Res. 4:345-349(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4385-5183 (ISOFORMS 1 AND
RP   2), AND VARIANT LEU-4867.
RC   TISSUE=Kidney, Liver, Lung, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4583-5183 (ISOFORM 1), AND VARIANTS
RP   LEU-4867 AND ARG-4924.
RX   PubMed=16247014; DOI=10.1073/pnas.0500090102;
RA   Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D.,
RA   Woelfel C., Huber C., Woelfel T.;
RT   "The response of autologous T cells to a human melanoma is dominated
RT   by mutated neoantigens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16013-16018(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4686-5183 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4709-5183 (ISOFORM 1), AND
RP   VARIANT LEU-4867.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   INTERACTION WITH HPV-16 E7; HPV-6B E7 AND HPV-11 E7, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=16061792; DOI=10.1073/pnas.0505337102;
RA   Huh K.-W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., Muenger K.;
RT   "Association of the human papillomavirus type 16 E7 oncoprotein with
RT   the 600-kDa retinoblastoma protein-associated factor, p600.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11492-11497(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181 AND
RP   THR-2715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1084, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181 AND
RP   SER-1763, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2719, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181; THR-905;
RP   SER-1747; SER-1878; SER-1904; THR-2715 AND SER-2719, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid
RT   biosynthesis and tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1647; SER-1652; THR-2944
RP   AND SER-2952, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-1394.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which is a component of the
CC       N-end rule pathway. Recognizes and binds to proteins bearing
CC       specific N-terminal residues that are destabilizing according to
CC       the N-end rule, leading to their ubiquitination and subsequent
CC       degradation. Together with clathrin, forms meshwork structures
CC       involved in membrane morphogenesis and cytoskeletal organization.
CC       Regulates integrin-mediated signaling. May play a role in
CC       activation of FAK in response to cell-matrix interactions.
CC       Mediates ubiquitination of ACLY, leading to its subsequent
CC       degradation. {ECO:0000269|PubMed:16214886,
CC       ECO:0000269|PubMed:23932781}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with RB1 and calmodulin. Interacts with protein
CC       E7 from papilloma virus HPV-16, HPV-6B and HPV-11.
CC       {ECO:0000269|PubMed:16061792, ECO:0000269|PubMed:16214886}.
CC   -!- INTERACTION:
CC       P03129:E7 (xeno); NbExp=5; IntAct=EBI-1995940, EBI-866453;
CC       P04020:E7 (xeno); NbExp=2; IntAct=EBI-1995940, EBI-7005254;
CC       P06464:E7 (xeno); NbExp=2; IntAct=EBI-1995940, EBI-6944797;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Cytoplasm. Cytoplasm, cytoskeleton.
CC       Nucleus. Note=Concentrates at the leading edge of membrane
CC       structures involved in actin motility.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=Q5T4S7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5T4S7-2; Sequence=VSP_025209;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q5T4S7-3; Sequence=VSP_025203, VSP_025206;
CC       Name=4;
CC         IsoId=Q5T4S7-4; Sequence=VSP_025205, VSP_025206;
CC       Name=5;
CC         IsoId=Q5T4S7-5; Sequence=VSP_025201, VSP_025202, VSP_025204;
CC       Name=6;
CC         IsoId=Q5T4S7-6; Sequence=VSP_025200, VSP_025207, VSP_025208;
CC   -!- SIMILARITY: Belongs to the UBR4 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD43719.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAI19271.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF348492; AAL83880.1; -; mRNA.
DR   EMBL; AK022322; BAB14011.1; -; mRNA.
DR   EMBL; AL137127; CAI19268.1; -; Genomic_DNA.
DR   EMBL; AL357564; CAI19268.1; JOINED; Genomic_DNA.
DR   EMBL; AL137127; CAI19269.1; -; Genomic_DNA.
DR   EMBL; AL357564; CAI19269.1; JOINED; Genomic_DNA.
DR   EMBL; AL137127; CAI19271.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL137127; CAI19272.1; -; Genomic_DNA.
DR   EMBL; AL357564; CAI19272.1; JOINED; Genomic_DNA.
DR   EMBL; AL137127; CAI19273.1; -; Genomic_DNA.
DR   EMBL; AL137127; CAI19274.1; -; Genomic_DNA.
DR   EMBL; AL357564; CAI20972.1; -; Genomic_DNA.
DR   EMBL; AL137127; CAI20972.1; JOINED; Genomic_DNA.
DR   EMBL; AL357564; CAI20973.1; -; Genomic_DNA.
DR   EMBL; AL137127; CAI20973.1; JOINED; Genomic_DNA.
DR   EMBL; AL357564; CAI20974.1; -; Genomic_DNA.
DR   EMBL; AL137127; CAI20974.1; JOINED; Genomic_DNA.
DR   EMBL; AB037728; BAA92545.1; -; mRNA.
DR   EMBL; AB007931; BAA32307.1; -; mRNA.
DR   EMBL; BC018694; AAH18694.2; -; mRNA.
DR   EMBL; BC063573; AAH63573.1; -; mRNA.
DR   EMBL; BC073905; AAH73905.1; -; mRNA.
DR   EMBL; BC096758; AAH96758.1; -; mRNA.
DR   EMBL; AJ505016; CAD43719.1; ALT_INIT; mRNA.
DR   EMBL; AL049972; CAB43227.1; -; mRNA.
DR   EMBL; AF055010; AAC09360.1; -; mRNA.
DR   CCDS; CCDS189.1; -. [Q5T4S7-1]
DR   PIR; T00076; T00076.
DR   RefSeq; NP_065816.2; NM_020765.2. [Q5T4S7-1]
DR   UniGene; Hs.148078; -.
DR   UniGene; Hs.649405; -.
DR   ProteinModelPortal; Q5T4S7; -.
DR   BioGrid; 116934; 107.
DR   IntAct; Q5T4S7; 43.
DR   MINT; MINT-4715511; -.
DR   STRING; 9606.ENSP00000364403; -.
DR   DrugBank; DB04959; HspE7.
DR   DrugBank; DB05483; PCL-016.
DR   iPTMnet; Q5T4S7; -.
DR   PhosphoSitePlus; Q5T4S7; -.
DR   SwissPalm; Q5T4S7; -.
DR   BioMuta; UBR4; -.
DR   DMDM; 74744979; -.
DR   EPD; Q5T4S7; -.
DR   MaxQB; Q5T4S7; -.
DR   PaxDb; Q5T4S7; -.
DR   PeptideAtlas; Q5T4S7; -.
DR   PRIDE; Q5T4S7; -.
DR   Ensembl; ENST00000375218; ENSP00000364366; ENSG00000127481. [Q5T4S7-6]
DR   Ensembl; ENST00000375254; ENSP00000364403; ENSG00000127481. [Q5T4S7-1]
DR   GeneID; 23352; -.
DR   KEGG; hsa:23352; -.
DR   UCSC; uc001bbi.4; human. [Q5T4S7-1]
DR   CTD; 23352; -.
DR   DisGeNET; 23352; -.
DR   GeneCards; UBR4; -.
DR   H-InvDB; HIX0000191; -.
DR   HGNC; HGNC:30313; UBR4.
DR   HPA; HPA013394; -.
DR   HPA; HPA021046; -.
DR   MIM; 609890; gene.
DR   neXtProt; NX_Q5T4S7; -.
DR   OpenTargets; ENSG00000127481; -.
DR   PharmGKB; PA162407958; -.
DR   eggNOG; KOG1776; Eukaryota.
DR   eggNOG; ENOG410XPP8; LUCA.
DR   GeneTree; ENSGT00600000084471; -.
DR   HOVERGEN; HBG058328; -.
DR   InParanoid; Q5T4S7; -.
DR   KO; K10691; -.
DR   OMA; EGDVHTS; -.
DR   OrthoDB; EOG091G000I; -.
DR   PhylomeDB; Q5T4S7; -.
DR   TreeFam; TF314406; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBR4; human.
DR   GeneWiki; UBR4; -.
DR   GenomeRNAi; 23352; -.
DR   PRO; PR:Q5T4S7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000127481; -.
DR   ExpressionAtlas; Q5T4S7; baseline and differential.
DR   Genevisible; Q5T4S7; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR025704; E3_Ub_ligase_UBR4.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR003126; Znf_UBR.
DR   Pfam; PF13764; E3_UbLigase_R4; 1.
DR   Pfam; PF02207; zf-UBR; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   SUPFAM; SSF48371; SSF48371; 9.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Calmodulin-binding;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Host-virus interaction; Membrane; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase;
KW   Transmembrane; Transmembrane helix; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   5183       E3 ubiquitin-protein ligase UBR4.
FT                                /FTId=PRO_0000286861.
FT   TRANSMEM    850    870       Helical. {ECO:0000255}.
FT   TRANSMEM    993   1013       Helical. {ECO:0000255}.
FT   ZN_FING    1656   1729       UBR-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00508}.
FT   COMPBIAS      9     15       Poly-Ala.
FT   COMPBIAS    608    631       Pro-rich.
FT   COMPBIAS   2728   2738       Poly-Asp.
FT   COMPBIAS   3339   3370       Ser-rich.
FT   MOD_RES     178    178       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     181    181       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     212    212       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2AN08}.
FT   MOD_RES     370    370       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:A2AN08}.
FT   MOD_RES     905    905       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1084   1084       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1402   1402       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q2TL32}.
FT   MOD_RES    1647   1647       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1652   1652       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1747   1747       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1754   1754       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q2TL32}.
FT   MOD_RES    1763   1763       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1878   1878       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1904   1904       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2715   2715       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2719   2719       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|Ref.4}.
FT   MOD_RES    2722   2722       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2AN08}.
FT   MOD_RES    2724   2724       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:A2AN08}.
FT   MOD_RES    2944   2944       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2952   2952       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1   3585       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_025200.
FT   VAR_SEQ    2100   2100       K -> KQ (in isoform 5).
FT                                {ECO:0000303|PubMed:10718198}.
FT                                /FTId=VSP_025201.
FT   VAR_SEQ    2405   2486       IGASVDPAGVTMIDAVKIYGKTKEQFGWPDEPPEEFPSASV
FT                                SNICPSNLNQSNGTGDSDSAAPTTTSGTVLERLVVSSLEAL
FT                                -> SESPTPGADSVLIVTAKLGATGLWLSNILGSLHSADFS
FT                                VLSSGNFELHLMY (in isoform 5).
FT                                {ECO:0000303|PubMed:10718198}.
FT                                /FTId=VSP_025202.
FT   VAR_SEQ    2476   2476       E -> ESSETESLTKLD (in isoform 3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_025203.
FT   VAR_SEQ    2487   5183       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:10718198}.
FT                                /FTId=VSP_025204.
FT   VAR_SEQ    2601   2601       T -> TDCFFPRCACWSLGIVGILIGAPLETPSP (in
FT                                isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_025205.
FT   VAR_SEQ    2830   2864       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_025206.
FT   VAR_SEQ    3777   3797       DDSGTAGGISSTSASVNRYIL -> VVPRCKGHLDKGLGLD
FT                                QKTAS (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_025207.
FT   VAR_SEQ    3798   5183       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_025208.
FT   VAR_SEQ    5108   5108       K -> KKQTTPTVGGIDTGSLEPCVCE (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_025209.
FT   VARIANT    1107   1107       T -> A (in dbSNP:rs16862578).
FT                                /FTId=VAR_032193.
FT   VARIANT    1394   1394       R -> H (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs756549939).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035540.
FT   VARIANT    4867   4867       M -> L (in dbSNP:rs12584).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16247014,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_032194.
FT   VARIANT    4924   4924       G -> R (in a melanoma patient).
FT                                {ECO:0000269|PubMed:16247014}.
FT                                /FTId=VAR_032195.
FT   VARIANT    5084   5084       V -> M (in dbSNP:rs2274010).
FT                                /FTId=VAR_032196.
FT   CONFLICT   2016   2016       A -> S (in Ref. 1; AAL83880).
FT                                {ECO:0000305}.
FT   CONFLICT   2410   2410       D -> E (in Ref. 1; AAL83880).
FT                                {ECO:0000305}.
FT   CONFLICT   3957   3957       G -> S (in Ref. 1; AAL83880).
FT                                {ECO:0000305}.
FT   CONFLICT   4589   4589       G -> V (in Ref. 7; AAH18694).
FT                                {ECO:0000305}.
SQ   SEQUENCE   5183 AA;  573841 MW;  5F6DD7B565E27609 CRC64;
     MATSGGEEAA AAAPAPGTPA TGADTTPGWE VAVRPLLSAS YSAFEMKELP QLVASVIESE
     SEILHHEKQY EPFYSSFVAL STHYITTVCS LIPRNQLQSV AAACKVLIEF SLLRLENPDE
     ACAVSQKHLI LLIKGLCTGC SRLDRTEIIT FTAMMKSAKL PQTVKTLSDV EDQKELASPV
     SPELRQKEVQ MNFLNQLTSV FNPRTVASQP ISTQTLVEGE NDEQSSTDQA SAIKTKNVFI
     AQNVASLQEL GGSEKLLRVC LNLPYFLRYI NRFQDAVLAN SFFIMPATVA DATAVRNGFH
     SLVIDVTMAL DTLSLPVLEP LNPSRLQDVT VLSLSCLYAG VSVATCMAIL HVGSAQQVRT
     GSTSSKEDDY ESDAATIVQK CLEIYDMIGQ AISSSRRAGG EHYQNFQLLG AWCLLNSLFL
     ILNLSPTALA DKGKEKDPLA ALRVRDILSR TKEGVGSPKL GPGKGHQGFG VLSVILANHA
     IKLLTSLFQD LQVEALHKGW ETDGPPAALS IMAQSTSIQR IQRLIDSVPL MNLLLTLLST
     SYRKACVLQR QRKGSMSSDA SASTDSNTYY EDDFSSTEED SSQDDDSEPI LGQWFEETIS
     PSKEKAAPPP PPPPPPLESS PRVKSPSKQA PGEKGNILAS RKDPELFLGL ASNILNFITS
     SMLNSRNNFI RNYLSVSLSE HHMATLASII KEVDKDGLKG SSDEEFAAAL YHFNHSLVTS
     DLQSPNLQNT LLQQLGVAPF SEGPWPLYIH PQSLSVLSRL LLIWQHKASA QGDPDVPECL
     KVWDRFLSTM KQNALQGVVP SETEDLNVEH LQMLLLIFHN FTETGRRAIL SLFVQIIQEL
     SVNMDAQMRF VPLILARLLL IFDYLLHQYS KAPVYLFEQV QHNLLSPPFG WASGSQDSNS
     RRATTPLYHG FKEVEENWSK HFSSDAVPHP RFYCVLSPEA SEDDLNRLDS VACDVLFSKL
     VKYDELYAAL TALLAAGSQL DTVRRKENKN VTALEACALQ YYFLILWRIL GILPPSKTYI
     NQLSMNSPEM SECDILHTLR WSSRLRISSY VNWIKDHLIK QGMKAEHASS LLELASTTKC
     SSVKYDVEIV EEYFARQISS FCSIDCTTIL QLHEIPSLQS IYTLDAAISK VQVSLDEHFS
     KMAAETDPHK SSEITKNLLP ATLQLIDTYA SFTRAYLLQN FNEEGTTEKP SKEKLQGFAA
     VLAIGSSRCK ANTLGPTLVQ NLPSSVQTVC ESWNNINTNE FPNIGSWRNA FANDTIPSES
     YISAVQAAHL GTLCSQSLPL AASLKHTLLS LVRLTGDLIV WSDEMNPPQV IRTLLPLLLE
     SSTESVAEIS SNSLERILGP AESDEFLARV YEKLITGCYN ILANHADPNS GLDESILEEC
     LQYLEKQLES SQARKAMEEF FSDSGELVQI MMATANENLS AKFCNRVLKF FTKLFQLTEK
     SPNPSLLHLC GSLAQLACVE PVRLQAWLTR MTTSPPKDSD QLDVIQENRQ LLQLLTTYIV
     RENSQVGEGV CAVLLGTLTP MATEMLANGD GTGFPELMVV MATLASAGQG AGHLQLHNAA
     VDWLSRCKKY LSQKNVVEKL NANVMHGKHV MILECTCHIM SYLADVTNAL SQSNGQGPSH
     LSVDGEERAI EVDSDWVEEL AVEEEDSQAE DSDEDSLCNK LCTFTITQKE FMNQHWYHCH
     TCKMVDGVGV CTVCAKVCHK DHEISYAKYG SFFCDCGAKE DGSCLALVKR TPSSGMSSTM
     KESAFQSEPR ISESLVRHAS TSSPADKAKV TISDGKVADE EKPKKSSLCR TVEGCREELQ
     NQANFSFAPL VLDMLNFLMD AIQTNFQQAS AVGSSSRAQQ ALSELHTVEK AVEMTDQLMV
     PTLGSQEGAF ENVRMNYSGD QGQTIRQLIS AHVLRRVAMC VLSSPHGRRQ HLAVSHEKGK
     ITVLQLSALL KQADSSKRKL TLTRLASAPV PFTVLSLTGN PCKEDYLAVC GLKDCHVLTF
     SSSGSVSDHL VLHPQLATGN FIIKAVWLPG SQTELAIVTA DFVKIYDLCV DALSPTFYFL
     LPSSKIRDVT FLFNEEGKNI IVIMSSAGYI YTQLMEEASS AQQGPFYVTN VLEINHEDLK
     DSNSQVAGGG VSVYYSHVLQ MLFFSYCQGK SFAATISRTT LEVLQLFPIN IKSSNGGSKT
     SPALCQWSEV MNHPGLVCCV QQTTGVPLVV MVKPDTFLIQ EIKTLPAKAK IQDMVAIRHT
     ACNEQQRTTM ILLCEDGSLR IYMANVENTS YWLQPSLQPS SVISIMKPVR KRKTATITTR
     TSSQVTFPID FFEHNQQLTD VEFGGNDLLQ VYNAQQIKHR LNSTGMYVAN TKPGGFTIEI
     SNNNSTMVMT GMRIQIGTQA IERAPSYIEI FGRTMQLNLS RSRWFDFPFT REEALQADKK
     LNLFIGASVD PAGVTMIDAV KIYGKTKEQF GWPDEPPEEF PSASVSNICP SNLNQSNGTG
     DSDSAAPTTT SGTVLERLVV SSLEALESCF AVGPIIEKER NKNAAQELAT LLLSLPAPAS
     VQQQSKSLLA SLHTSRSAYH SHKDQALLSK AVQCLNTSSK EGKDLDPEVF QRLVITARSI
     AIMRPNNLVH FTESKLPQME TEGMDEGKEP QKQLEGDCCS FITQLVNHFW KLHASKPKNA
     FLAPACLPGL THIEATVNAL VDIIHGYCTC ELDCINTASK IYMQMLLCPD PAVSFSCKQA
     LIRVLRPRNK RRHVTLPSSP RSNTPMGDKD DDDDDDADEK MQSSGIPNGG HIRQESQEQS
     EVDHGDFEMV SESMVLETAE NVNNGNPSPL EALLAGAEGF PPMLDIPPDA DDETMVELAI
     ALSLQQDQQG SSSSALGLQS LGLSGQAPSS SSLDAGTLSD TTASAPASDD EGSTAATDGS
     TLRTSPADHG GSVGSESGGS AVDSVAGEHS VSGRSSAYGD ATAEGHPAGP GSVSSSTGAI
     STTTGHQEGD GSEGEGEGET EGDVHTSNRL HMVRLMLLER LLQTLPQLRN VGGVRAIPYM
     QVILMLTTDL DGEDEKDKGA LDNLLSQLIA ELGMDKKDVS KKNERSALNE VHLVVMRLLS
     VFMSRTKSGS KSSICESSSL ISSATAAALL SSGAVDYCLH VLKSLLEYWK SQQNDEEPVA
     TSQLLKPHTT SSPPDMSPFF LRQYVKGHAA DVFEAYTQLL TEMVLRLPYQ IKKITDTNSR
     IPPPVFDHSW FYFLSEYLMI QQTPFVRRQV RKLLLFICGS KEKYRQLRDL HTLDSHVRGI
     KKLLEEQGIF LRASVVTASS GSALQYDTLI SLMEHLKACA EIAAQRTINW QKFCIKDDSV
     LYFLLQVSFL VDEGVSPVLL QLLSCALCGS KVLAALAASS GSSSASSSSA PVAASSGQAT
     TQSKSSTKKS KKEEKEKEKD GETSGSQEDQ LCTALVNQLN KFADKETLIQ FLRCFLLESN
     SSSVRWQAHC LTLHIYRNSS KSQQELLLDL MWSIWPELPA YGRKAAQFVD LLGYFSLKTP
     QTEKKLKEYS QKAVEILRTQ NHILTNHPNS NIYNTLSGLV EFDGYYLESD PCLVCNNPEV
     PFCYIKLSSI KVDTRYTTTQ QVVKLIGSHT ISKVTVKIGD LKRTKMVRTI NLYYNNRTVQ
     AIVELKNKPA RWHKAKKVQL TPGQTEVKID LPLPIVASNL MIEFADFYEN YQASTETLQC
     PRCSASVPAN PGVCGNCGEN VYQCHKCRSI NYDEKDPFLC NACGFCKYAR FDFMLYAKPC
     CAVDPIENEE DRKKAVSNIN TLLDKADRVY HQLMGHRPQL ENLLCKVNEA APEKPQDDSG
     TAGGISSTSA SVNRYILQLA QEYCGDCKNS FDELSKIIQK VFASRKELLE YDLQQREAAT
     KSSRTSVQPT FTASQYRALS VLGCGHTSST KCYGCASAVT EHCITLLRAL ATNPALRHIL
     VSQGLIRELF DYNLRRGAAA MREEVRQLMC LLTRDNPEAT QQMNDLIIGK VSTALKGHWA
     NPDLASSLQY EMLLLTDSIS KEDSCWELRL RCALSLFLMA VNIKTPVVVE NITLMCLRIL
     QKLIKPPAPT SKKNKDVPVE ALTTVKPYCN EIHAQAQLWL KRDPKASYDA WKKCLPIRGI
     DGNGKAPSKS ELRHLYLTEK YVWRWKQFLS RRGKRTSPLD LKLGHNNWLR QVLFTPATQA
     ARQAACTIVE ALATIPSRKQ QVLDLLTSYL DELSIAGECA AEYLALYQKL ITSAHWKVYL
     AARGVLPYVG NLITKEIARL LALEEATLST DLQQGYALKS LTGLLSSFVE VESIKRHFKS
     RLVGTVLNGY LCLRKLVVQR TKLIDETQDM LLEMLEDMTT GTESETKAFM AVCIETAKRY
     NLDDYRTPVF IFERLCSIIY PEENEVTEFF VTLEKDPQQE DFLQGRMPGN PYSSNEPGIG
     PLMRDIKNKI CQDCDLVALL EDDSGMELLV NNKIISLDLP VAEVYKKVWC TTNEGEPMRI
     VYRMRGLLGD ATEEFIESLD STTDEEEDEE EVYKMAGVMA QCGGLECMLN RLAGIRDFKQ
     GRHLLTVLLK LFSYCVKVKV NRQQLVKLEM NTLNVMLGTL NLALVAEQES KDSGGAAVAE
     QVLSIMEIIL DESNAEPLSE DKGNLLLTGD KDQLVMLLDQ INSTFVRSNP SVLQGLLRII
     PYLSFGEVEK MQILVERFKP YCNFDKYDED HSGDDKVFLD CFCKIAAGIK NNSNGHQLKD
     LILQKGITQN ALDYMKKHIP SAKNLDADIW KKFLSRPALP FILRLLRGLA IQHPGTQVLI
     GTDSIPNLHK LEQVSSDEGI GTLAENLLEA LREHPDVNKK IDAARRETRA EKKRMAMAMR
     QKALGTLGMT TNEKGQVVTK TALLKQMEEL IEEPGLTCCI CREGYKFQPT KVLGIYTFTK
     RVALEEMENK PRKQQGYSTV SHFNIVHYDC HLAAVRLARG REEWESAALQ NANTKCNGLL
     PVWGPHVPES AFATCLARHN TYLQECTGQR EPTYQLNIHD IKLLFLRFAM EQSFSADTGG
     GGRESNIHLI PYIIHTVLYV LNTTRATSRE EKNLQGFLEQ PKEKWVESAF EVDGPYYFTV
     LALHILPPEQ WRATRVEILR RLLVTSQARA VAPGGATRLT DKAVKDYSAY RSSLLFWALV
     DLIYNMFKKV PTSNTEGGWS CSLAEYIRHN DMPIYEAADK ALKTFQEEFM PVETFSEFLD
     VAGLLSEITD PESFLKDLLN SVP
//
